Evidence map›Paper›PMID 37189851›Full record

ArticleBiomedicines2023

Loss of the Novel Mitochondrial Membrane Protein FAM210B Is Associated with Hepatocellular Carcinoma.

Yuanqin Zhou, Xianzhu Pan, Yakun Liu, Xiaofei Li, Keqiong Lin, Jicheng Zhu, Li Zhan, Chen Kan, Hong Zheng

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuanqin ZhouDepartment of Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
Xianzhu PanDepartment of Pathology and Pathophysiology, School of Basic Medicine, Anhui Medical College, Hefei 230601, China.
Yakun LiuDepartment of Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
Xiaofei LiDepartment of Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
Keqiong LinDepartment of Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
Jicheng ZhuDepartment of Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
Li ZhanDepartment of Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.ORCID 0009-0004-4180-8206
Chen KanDepartment of Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
Hong ZhengDepartment of Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.ORCID 0000-0002-4048-6530
Anhui Medical University · CN

Funding

Grants for Postgraduate Scientific Research of Universities in Anhui Province YJS20210259National Natural Science Foundation of China 81670097, 81870085, and 82173004
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is an aggressive and challenging disease to treat. Due to the lack of effective early diagnosis and therapy for the illness, it is crucial to identify novel biomarkers that can predict tumor behavior in HCC. In such cases, family with sequence similarity 210 member B (FAM210B) is abundant in various human tissues, but its regulatory mechanisms and role in various tissues remain unclear. In this study, we analyzed the expression pattern of FAM210B in HCC using public gene expression databases and clinical tissue samples. Our results confirmed that FAM210B was dysregulated in both HCC cell lines and HCC paraffin section samples. FAM210B depletion significantly increased the capacity of cells to grow, migrate, and invade in vitro, while overexpression of FAM210B suppressed tumor growth in a xenograft tumor model. Furthermore, we identified FAM210B's involvement in MAPK signaling and p-AKT signaling pathways, both of which are known oncogenic signaling pathways. In summary, our study provides a rational basis for the further investigation of FAM210B as a valuable biological marker for diagnosing and predicting the prognosis of HCC patients.

Indexed as

FAM210Bhepatocellular carcinomaMAPK signalingmetastasismitochondrial membrane proteinPI3K/AKT signaling

Identifiers

PMID37189851
PMCPMC10135939
OpenAlexW4366774316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.